Key result
Isradipine is linked to lower systolic and diastolic BP in hypertensive patients with diabetes.
Why the study?
Does isradipine reduce blood pressure in hypertensive diabetic patients?
Does isradipine reduce blood pressure in hypertensive diabetic patients?
Isradipine effectively reduces systolic and diastolic blood pressure in hypertensive patients with type I or type II diabetes over 6 months without adversely affecting metabolic control.
Answers are grounded in this paper and cite their sources.
Supports isradipine for BP reduction in diabetic hypertension; leaves open need for randomized confirmation before practice change.
The aim of this study was to investigate the efficacy, tolerability, and safety of isradipine in hypertensive diabetic patients. Twenty-eight patients (14 men and 14 women), of whom 15 had type II (non-insulin-dependent) and 13 had type I (insulin-dependent) diabetes mellitus, received isradipine for 6 months. A significant reduction was observed in both systolic and diastolic blood pressures (P < .00005). There were no significant differences between the type I and type II diabetes patients; metabolic control remained stable. Moderate or slight headaches were reported by four patients. In conclusion, the overall efficacy of isradipine and its tolerability were found to be very good.
No takes yet. Share an insight, caveat, or question.
Parreira et al. (1993) studied Hypertension with diabetes (n=28). Isradipine was evaluated on Systolic and diastolic blood pressures (p=<.00005). Isradipine significantly reduced both systolic and diastolic blood pressures in hypertensive patients with diabetes over 6 months (P < .00005).
Synapse has enriched 10 related papers. Consider them for comparative context: